MBRX Moleculin Biotech, Inc.
Price Chart
Executive Summary
Moleculin Biotech announced preliminary blinded data from its pivotal Phase 2B/3 MIRACLE trial for Annamycin in relapsed/refractory AML, showing a complete remission rate of approximately 30% vs historical ~17-18% for standard of care. The first unblinding of 45 subjects is expected before June 30, 2026, representing a potential catalyst. Recruitment is on track with 56 of 90 subjects enrolled.
Actionable Insight
Monitor for unblinding results before June 30, 2026 – positive data could drive substantial upside given small market cap. Risk of dilution remains as company needs additional financing.
Key Facts
- Preliminary blinded CR rate approximates 30%, representing ~67% improvement over historical benchmarks of ~17-18%
- First data unblinding of 45 subjects expected before June 30, 2026
- 56 subjects recruited to date (62% of Part A target of 90 subjects)
- Trial includes two Annamycin doses + cytarabine vs cytarabine + placebo
- Over 30% of enrolled patients had prior venetoclax treatment, a challenging subgroup
Financial Impact
No revenue reported; clinical milestone could significantly affect stock price for this $12M market cap biotech
Risk Factors
- Unblinded data may not confirm preliminary blinded results
- Company requires significant additional financing with no commitments
- Clinical trial risk: failure to meet primary endpoint
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-016535 |
| Exhibit: ex_960684.htm | 0001437749-26-016535 |
| Document: 0001437749-26-016535-index-headers.html | 0001437749-26-016535 |
| Document: 0001437749-26-016535-index.html | 0001437749-26-016535 |
| Document: 0001437749-26-016535.txt | 0001437749-26-016535 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
4d ago
|
8-K
| $2.58 awaiting T+5 | awaiting T+5 | — | $2.47 (−4.26%) |
|
May 29, 2026
11d ago
|
8-K
| $2.79 $2.46 | ▼ −11.83% | ▼ −11.54% | $2.47 (−11.47%) |
|
May 26, 2026
14d ago
|
8-K
| $2.45 $2.64 | ▲ +7.76% | ▲ +6.67% | $2.47 (+0.82%) |
|
May 22, 2026
18d ago
|
8-K
| $2.45 $2.64 | ▲ +7.76% | ▲ +6.67% | $2.47 (+0.82%) |
|
May 15, 2026
25d ago
|
8-K
| $2.11 $2.39 | ▲ +13.27% | ▲ +12.31% | $2.47 (+17.06%) |
|
May 15, 2026
25d ago
|
Press Release
| $2.11 $2.39 | ▼ −13.27% | ▼ −12.31% | $2.47 (−17.06%) |
|
May 13, 2026
27d ago
|
8-K
| $2.14 $2.35 | ▲ +9.81% | ▲ +10.97% | $2.47 (+15.42%) |
|
May 12, 2026
28d ago
|
8-K
| $2.34 $2.09 | ▼ −10.68% | ▼ −10.76% | $2.47 (+5.56%) |
|
May 8, 2026
4w ago
|
8-K
| $2.47 $2.20 | ▼ −10.93% | ▼ −12.39% | $2.47 (+0.00%) |
|
Apr 23, 2026
6w ago
|
8-K
| $2.54 $2.51 | ▼ −1.18% | ▼ −2.66% | $2.47 (−2.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access